Cargando…
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202....
Autores principales: | Steinhardt, Maximilian Johannes, Zhou, Xiang, Krummenast, Franziska, Meckel, Katharina, Nickel, Katharina, Böckle, David, Messerschmidt, Janin, Knorz, Sebastian, Dierks, Alexander, Heidemeier, Anke, Lapa, Constantin, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768838/ https://www.ncbi.nlm.nih.gov/pubmed/33353443 http://dx.doi.org/10.1177/2058738420980258 |
Ejemplares similares
-
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020) -
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020) -
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020) -
The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT
por: Zhou, Xiang, et al.
Publicado: (2020) -
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
por: Steinhardt, Maximilian J., et al.
Publicado: (2021)